KBC Group’s MBX Biosciences MBX Stock Holding History

KBC Group’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$47K	Hold	810	–	–	﹤0.01%	1739
2026 Q2	$45K	Hold	810	–	–	﹤0.01%	1742
2026 Q1	$24K	Buy	+810	New	+$27.5K	﹤0.01%	1829

Other funds holding MBX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

KBC Group's MBX Position: Q3 2026 in Review

KBC Group held its MBX Biosciences (MBX) position steady in Q3 2026 at 810 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

KBC Group first reported a position in MBX in Q1 2026 and has held it in 3 quarters since. 95 funds tracked by Wall St. Rank hold MBX as of Q3 2026.

KBC Group held 810 shares of MBX Biosciences worth $47K as of Q3 2026.
KBC Group left its MBX Biosciences share count unchanged in Q3 2026.
MBX Biosciences made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1739 holding.
KBC Group first reported a position in MBX Biosciences in Q1 2026 and has held it in 3 quarters since.
95 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.